Welcome to our dedicated page for bioAffinity Tech news (Ticker: BIAF), a resource for investors and traders seeking the latest updates and insights on bioAffinity Tech stock.
bioAffinity Technologies Inc (BIAF) delivers pioneering noninvasive diagnostics for early cancer detection through advanced flow cytometry solutions. This dedicated news center provides investors and medical professionals with timely updates on the company’s scientific advancements and strategic growth.
Access official press releases covering regulatory milestones, clinical study results, and partnership agreements. Key focus areas include developments around the CyPath Lung test, licensing expansions, and financial performance reports. Our curated feed ensures you stay informed about BIAF’s contributions to reducing invasive diagnostic procedures in oncology.
Explore updates categorized for clarity: earnings announcements, FDA submissions, collaborative research initiatives, and technological enhancements to cellular analysis platforms. Bookmark this page or check regularly to monitor how bioAffinity’s innovations in cellular oncology are reshaping diagnostic standards.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) reports an increase in sales of CyPath® Lung, their noninvasive diagnostic test for lung cancer detection. April sales were up 21% from March, with new orders from physicians in various states. The company also welcomed new team members to support the CyPath® Lung product launch. Additionally, bioAffinity will present research at the American Thoracic Society's Annual Conference.
FAQ
What is the current stock price of bioAffinity Tech (BIAF)?
What is the market cap of bioAffinity Tech (BIAF)?
